Principal Investigators

Prof. Mike Waring

Mike was appointed in 2015 from AstraZeneca where he had worked for 14 years across a range of drug discovery projects in cancer and diabetes, leading the chemistry in teams that discovered 14 clinical candidates including the launched mutant EGFR inhibitor Tagrisso™ (osimertinib). He is an expert in lead generation and physical property based optimisation and has published extensively in these fields. His work has been recognised by a number of international awards (2010 RSC Capps-Green-Zomaya Medal, 2010 EFMC Young Medicinal Chemist Prize, 2014 Inaugural RSC Biological and Medicinal Chemistry Lectureship, 2017 RSC Malcolm Campbell Medal, 2018 ACS Hero of Chemistry). Mike is Director of the EPSRC Centre for Doctoral Training in Molecular Sciences for Medicine and is Head of Medicinal Chemistry in the CRUK Newcastle Drug Discovery Unit. University profile.